Susan Klein - Academia.edu (original) (raw)

Papers by Susan Klein

The United States Department of Energy has the right to use this thesis for any purpose whatsoeve... more The United States Department of Energy has the right to use this thesis for any purpose whatsoever including the right to reproduce all or any part thereof. & Patrick Echlin, and Greg Finch provided scientific guidance and support without which this work would not have been completed. Fred Wilt generously gave of his time, advice and laboratory space. Marylin Nichols, Dulcinea Wilson and Dorothy Sprague assisted with secretarial labors above and beyond the call of duty. May McKoon is remembered for her diligent and loving tutelage. My family, Stan, Calla and Joanne Klein, all supported and encouraged me in their own manner. Most of all, I wish to acknowledge the love and patience of James A. Musser. •.

PACS2001. Proceedings of the 2001 Particle Accelerator Conference (Cat. No.01CH37268), 2001

Funding to convert the IUCF K220 separated sector cyclotrons into a dedicated proton source for C... more Funding to convert the IUCF K220 separated sector cyclotrons into a dedicated proton source for Cancer Therapy was released by Indiana University in August of 2000. Phase I of the Midwest Proton Radiation Institute (MPRI) will initially consist of the IUCF separated sector cyclotrons upgraded to operate at a fixed energy of 205 MeV, a treatment room containing both a general purpose large field horizontal fixed line and a small field line for the treatment of eye melanoma, a second treatment room with a 360 o rotating Gantry, and a comprehensive medical clinic. A third treatment room with a gantry is incorporated into the beam delivery system design as a future upgrade. The MPRI beam delivery system is now under construction and will incorporate a beam sharing system to allow simultaneous beam delivery to all medical treatment rooms, as well as to medical and commercial research facilities. Additional Funding is anticipated for the construction of a dedicated Radiation Effects Research (RERP) facility for NASA and other commercial users requiring beam similar to those used for proton therapy. This report will outline the goals and design of the MPRI medical and commercial facilities, its present construction status and projected completion schedules.

Proceedings of the 2003 Bipolar/BiCMOS Circuits and Technology Meeting (IEEE Cat. No.03CH37440), 2003

Phase I construction of the Indiana University Midwest Proton Radiotherapy Institute (MPRI), incl... more Phase I construction of the Indiana University Midwest Proton Radiotherapy Institute (MPRI), including many reliability upgrades to the IUCF k220 cyclotron, construction of a variable energy proton Beam Delivery System (BDS), a horizontal beam Treatment Room with a Large Field Nozzle, and a Medical Clinic, is now complete. Commissioning of the BDS and the Large Field Nozzle is underway. Patient Treatment with this nozzle is scheduled to begin in late July 2003. This contribution discusses the unique features of the MPRI Cancer Treatment facility and the present Phase I commissioning results. In addition, two 360 0 rotating gantry systems were purchased from IBA in December 2002 for Phase II construction. The first gantry is scheduled for delivery in July 2003. The Phase II construction and installation schedule will also be briefly presented.

Technology in cancer research & treatment, Oct 17, 2015

Proton therapy dose is affected by relative biological effectiveness differently than X-ray thera... more Proton therapy dose is affected by relative biological effectiveness differently than X-ray therapies. The current clinically accepted weighting factor is 1.1 at all positions along the depth-dose profile. However, the relative biological effectiveness correlates with the linear energy transfer, cell or tissue type, and the dose per fraction causing variation of relative biological effectiveness along the depth-dose profile. In this article, we present a simple relative biological effectiveness-weighted treatment planning risk assessment algorithm in 2-dimensions and compare the results with those derived using the standard relative biological effectiveness of 1.1. The isodose distribution profiles for beams were accomplished using matrices that represent coplanar intersecting beams. These matrices were combined and contoured using MATLAB to achieve the distribution of dose. There are some important differences in dose distribution between the dose profiles resulting from the use of...

Technology in cancer research & treatment, Jan 17, 2015

Proton therapy dose is affected by relative biological effectiveness differently than X-ray thera... more Proton therapy dose is affected by relative biological effectiveness differently than X-ray therapies. The current clinically accepted weighting factor is 1.1 at all positions along the depth-dose profile. However, the relative biological effectiveness correlates with the linear energy transfer, cell or tissue type, and the dose per fraction causing variation of relative biological effectiveness along the depth-dose profile. In this article, we present a simple relative biological effectiveness-weighted treatment planning risk assessment algorithm in 2-dimensions and compare the results with those derived using the standard relative biological effectiveness of 1.1. The isodose distribution profiles for beams were accomplished using matrices that represent coplanar intersecting beams. These matrices were combined and contoured using MATLAB to achieve the distribution of dose. There are some important differences in dose distribution between the dose profiles resulting from the use of...

The United States Department of Energy has the right to use this thesis for any purpose whatsoeve... more The United States Department of Energy has the right to use this thesis for any purpose whatsoever including the right to reproduce all or any part thereof. & Patrick Echlin, and Greg Finch provided scientific guidance and support without which this work would not have been completed. Fred Wilt generously gave of his time, advice and laboratory space. Marylin Nichols, Dulcinea Wilson and Dorothy Sprague assisted with secretarial labors above and beyond the call of duty. May McKoon is remembered for her diligent and loving tutelage. My family, Stan, Calla and Joanne Klein, all supported and encouraged me in their own manner. Most of all, I wish to acknowledge the love and patience of James A. Musser. •.

PACS2001. Proceedings of the 2001 Particle Accelerator Conference (Cat. No.01CH37268), 2001

Funding to convert the IUCF K220 separated sector cyclotrons into a dedicated proton source for C... more Funding to convert the IUCF K220 separated sector cyclotrons into a dedicated proton source for Cancer Therapy was released by Indiana University in August of 2000. Phase I of the Midwest Proton Radiation Institute (MPRI) will initially consist of the IUCF separated sector cyclotrons upgraded to operate at a fixed energy of 205 MeV, a treatment room containing both a general purpose large field horizontal fixed line and a small field line for the treatment of eye melanoma, a second treatment room with a 360 o rotating Gantry, and a comprehensive medical clinic. A third treatment room with a gantry is incorporated into the beam delivery system design as a future upgrade. The MPRI beam delivery system is now under construction and will incorporate a beam sharing system to allow simultaneous beam delivery to all medical treatment rooms, as well as to medical and commercial research facilities. Additional Funding is anticipated for the construction of a dedicated Radiation Effects Research (RERP) facility for NASA and other commercial users requiring beam similar to those used for proton therapy. This report will outline the goals and design of the MPRI medical and commercial facilities, its present construction status and projected completion schedules.

Proceedings of the 2003 Bipolar/BiCMOS Circuits and Technology Meeting (IEEE Cat. No.03CH37440), 2003

Phase I construction of the Indiana University Midwest Proton Radiotherapy Institute (MPRI), incl... more Phase I construction of the Indiana University Midwest Proton Radiotherapy Institute (MPRI), including many reliability upgrades to the IUCF k220 cyclotron, construction of a variable energy proton Beam Delivery System (BDS), a horizontal beam Treatment Room with a Large Field Nozzle, and a Medical Clinic, is now complete. Commissioning of the BDS and the Large Field Nozzle is underway. Patient Treatment with this nozzle is scheduled to begin in late July 2003. This contribution discusses the unique features of the MPRI Cancer Treatment facility and the present Phase I commissioning results. In addition, two 360 0 rotating gantry systems were purchased from IBA in December 2002 for Phase II construction. The first gantry is scheduled for delivery in July 2003. The Phase II construction and installation schedule will also be briefly presented.

Technology in cancer research & treatment, Oct 17, 2015

Proton therapy dose is affected by relative biological effectiveness differently than X-ray thera... more Proton therapy dose is affected by relative biological effectiveness differently than X-ray therapies. The current clinically accepted weighting factor is 1.1 at all positions along the depth-dose profile. However, the relative biological effectiveness correlates with the linear energy transfer, cell or tissue type, and the dose per fraction causing variation of relative biological effectiveness along the depth-dose profile. In this article, we present a simple relative biological effectiveness-weighted treatment planning risk assessment algorithm in 2-dimensions and compare the results with those derived using the standard relative biological effectiveness of 1.1. The isodose distribution profiles for beams were accomplished using matrices that represent coplanar intersecting beams. These matrices were combined and contoured using MATLAB to achieve the distribution of dose. There are some important differences in dose distribution between the dose profiles resulting from the use of...

Technology in cancer research & treatment, Jan 17, 2015

Proton therapy dose is affected by relative biological effectiveness differently than X-ray thera... more Proton therapy dose is affected by relative biological effectiveness differently than X-ray therapies. The current clinically accepted weighting factor is 1.1 at all positions along the depth-dose profile. However, the relative biological effectiveness correlates with the linear energy transfer, cell or tissue type, and the dose per fraction causing variation of relative biological effectiveness along the depth-dose profile. In this article, we present a simple relative biological effectiveness-weighted treatment planning risk assessment algorithm in 2-dimensions and compare the results with those derived using the standard relative biological effectiveness of 1.1. The isodose distribution profiles for beams were accomplished using matrices that represent coplanar intersecting beams. These matrices were combined and contoured using MATLAB to achieve the distribution of dose. There are some important differences in dose distribution between the dose profiles resulting from the use of...